Oral Nitrate Selection for Transition from IV Therapy
When transitioning from intravenous nitroglycerin, either isosorbide dinitrate (5-80 mg 2-3 times daily) or isosorbide mononitrate (20 mg twice daily or 60-240 mg once daily sustained-release) should be used, administered in a non-tolerance-producing regimen with a 10-12 hour nitrate-free interval. 1
Timing of Transition
- Transition should occur within 24 hours once patients have been free of ischemic symptoms for 12-24 hours 1, 2
- Continuing IV nitroglycerin beyond this timeframe is not appropriate in stabilized patients without ongoing ischemia 1
- The dose of IV nitroglycerin should be gradually reduced before discontinuation, as abrupt cessation has been associated with exacerbation of ischemic ECG changes 1
Oral Nitrate Options
Isosorbide Dinitrate
- Standard formulation: 5-80 mg administered 2-3 times daily with duration of effect up to 8 hours 1, 2
- Sustained-release: 40 mg given 1-2 times daily with duration up to 8 hours 1, 2
Isosorbide Mononitrate (Preferred for Once-Daily Dosing)
- Standard formulation: 20 mg twice daily with 12-24 hour duration of effect 1, 2
- Sustained-release: 60-240 mg once daily 1, 2
Critical Tolerance Prevention Strategy
The most important consideration is preventing nitrate tolerance through intermittent dosing:
- Ensure a 10-12 hour nitrate-free interval daily to maintain efficacy and prevent tolerance development 1, 2
- Tolerance becomes clinically important after 24 hours of continuous therapy with any nitrate formulation 1
- For twice-daily dosing, use eccentric timing (e.g., 8 AM and 2 PM) rather than evenly spaced intervals 3, 4
- The nitrate-free period is typically scheduled at night and can be covered by other anti-ischemic medications (beta-blockers, calcium channel blockers) if needed 5, 4
Alternative: Transdermal Nitroglycerin
- Transdermal patches: 0.2-0.8 mg/hour applied for 12 hours daily (not 24 hours) with 8-12 hour duration during intermittent therapy 1, 2
- Must be removed for 12 hours daily to prevent tolerance 1, 2
Common Pitfalls to Avoid
- Do not prescribe continuous 24-hour nitrate coverage - this leads to rapid tolerance development and loss of anti-ischemic efficacy 1
- Do not abruptly stop IV nitroglycerin - taper the dose gradually to prevent rebound ischemia 1
- Do not use nitrates in patients who have taken phosphodiesterase-5 inhibitors within 12 hours (avanafil), 24 hours (sildenafil/vardenafil), or 48 hours (tadalafil) 6, 7
- Avoid in hypotensive patients with systolic blood pressure <90 mm Hg or >30 mm Hg below baseline 1, 6, 7
Practical Conversion Method
The ACC/AHA guidelines reference that a practical method for converting IV to topical nitroglycerin has been published, though specific conversion formulas are not detailed in the guidelines themselves 1, 2
Evidence Quality Note
The guidelines acknowledge that most studies of nitrate treatment in unstable angina/NSTEMI have been small and uncontrolled, with no randomized placebo-controlled trials addressing symptom relief or cardiac event reduction 1. Large trials (ISIS-4, GISSI-3) did not demonstrate mortality benefit with routine nitrate use, though these were confounded by frequent open-label nitrate use in control groups 1, 8.